1. Weill Cornell Medicine, USA
2. University of Nottingham, UK

Abstract

The neurotrophin receptor family of RTKs include tropomyosin-related kinase (Trk) receptors TrkA, TrkB and TrkC. Their cognate ligands are NGF, BDNF and neurotrophin-3, respectively. They are associated primarily with proliferative and migration effects in neural systems. Various isoforms of neurotrophin receptors exist, including truncated forms of TrkB and TrkC, which lack catalytic domains. p75 (TNFRSF16, also known as nerve growth factor receptor) can interact with neurotrophins and their propeptides. While p75 can lead to apoptosis, it can also form a complex with Trk receptors to mediate survival signalling [10].

Contents

GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a reference work which is most usefully represented as an on-line database. As in any publication this work should be appropriately cited, and the papers it cites should also be recognized. This document provides a citation for the relevant parts of the database, and also provides a reference list for the research cited by those parts. For further details see [8].

Please note that the database version for the citations given in GtoPdb are to the most recent preceding version in which the family or its subfamilies and targets were substantially changed. The links below are to the current version. If you need to consult the cited version, rather than the most recent version, please contact the GtoPdb curators.

Database links

References

1. Albaugh P, Fan Y, Mi Y, Sun F, Adrian F, Li N, Jia Y, Sarkisova Y, Kreusch A and Hood T et al.. (2012) Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models. ACS Med Chem Lett 3: 140-5 [PMID:24900443]
2. Allen S, Andrews SW, Baer B, Crane Z, Liu W and Watson DJ. (2015) 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor Patent number: WO2015175788A1. Assignee: Array Biopharma Inc.. Priority date: 15/05/2014. Publication date: 19/11/2015.
3. Anastassiadis T, Deacon SW, Devarajan K, Ma H and Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 29: 1039-45 [PMID:22037377]
4. Artim SC, Mendrola JM and Lemmon MA. (2012) Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family. Biochem J 448: 213-20 [PMID:22992069]
5. AstraZeneca. AZD1332. http://openinnovation.astrazeneca.com/what-we-offer/compound/azd1332/. Accessed on 11/09/2014.
6. Bertrand T, Kothe M, Liu J, Dupuy A, Rak A, Berne PF, Davis S, Gladysheva T, Valtre C and Crenne JY et al.. (2012) The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition. J Mol Biol 423: 439-53 [PMID:22902478]
7. Brasca MG, Amboldi N, Ballinari D, Cameron A, Casale E, Cervi G, Colombo M, Colotta F, Croci V and D'Alessio R et al.. (2009) Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem 52: 5152-63 [PMID:19603809]
8. Buneman P, Christie G, Davies JA, Dimitrellou R, Harding SD, Pawson AJ, Sharman JL and Wu Y. (2020) Why data citation isn't working, and what to do about it Database 2020 [PMID:32367113]
9. Cazorla M, Prémont J, Mann A, Girard N, Kellendonk C and Rognan D. (2011) Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. J Clin Invest 121: 1846-57 [PMID:21505263]
10. Conroy JN and Coulson EJ. (2022) High-affinity TrkA and p75 neurotrophin receptor complexes: A twisted affair. J Biol Chem 298: 101568 [PMID:35051416]
11. Dahlström M, Madjid N, Nordvall G, Halldin MM, Vazquez-Juarez E, Lindskog M, Sandin J, Winblad B, Eriksdotter M and Forsell P. (2021) Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction. Cells 10: 1871 [PMID:34440640]
12. Davies A, Ioannidis S, Lamb M, Su M, Wang T and Zhang H-J. (2013) 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancer Patent number: US8486966B2. Assignee: AstraZeneca AB. Priority date: 04/05/2007. Publication date: 17/07/2013.
13. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK and Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29: 1046-51 [PMID:22037378]
14. Dechant G, Tsoulfas P, Parada LF and Barde YA. (1997) The neurotrophin receptor p75 binds neurotrophin-3 on sympathetic neurons with high affinity and specificity. J Neurosci 17: 5281-7 [PMID:9204912]
15. Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, Zhu VW, Ahn MJ, Camidge DR and Nguyen J et al.. (2018) Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. Cancer Discov 8: 1227-1236 [PMID:30093503]
16. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R and Harvey KJ. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem J 451: 313-28 [PMID:23398362]
17. Guo J, Xiang S, Wang J, Zhou Y, Wang Z, Zhang Z, Ding K and Lu X. (2022) Discovery of novel TrkA allosteric inhibitors: Structure-based virtual screening, biological evaluation and preliminary SAR studies. Eur J Med Chem 228: 114022 [PMID:34871843]
18. Haas J, Andrews SW, Jiang Y and Zhang G. (2010) Substituted pyrazolo[1,5-a]pyrimidine compounds as TRK kinase inhibitors. Patent number: WO2010048314 A1. Assignee: Array Biopharma Inc.. Priority date: 22/10/2008. Publication date: 29/04/2010.
19. Horan JC, Tang X, Mente SR, Pelish HE, Shair MD and Tangpeerachaikul A. (2023) Heteroaromatic macrocyclic ether chemotherapeutic agents Patent number: US11542278. Assignee: Nuvalent, Inc.. Priority date: 29/10/2021. Publication date: 03/01/2023.
20. Huang Q, Johnson TW, Bailey S, Brooun A, Bunker KD, Burke BJ, Collins MR, Cook AS, Cui JJ and Dack KN et al.. (2014) Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem 57: 1170-87 [PMID:24432909]
21. Hudkins RL, Becknell NC, Zulli AL, Underiner TL, Angeles TS, Aimone LD, Albom MS, Chang H, Miknyoczki SJ and Hunter K et al.. (2012) Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent. J Med Chem 55: 903-13 [PMID:22148921]
22. Hudkins RL, Johnson NW, Angeles TS, Gessner GW and Mallamo JP. (2007) Synthesis and mixed lineage kinase activity of pyrrolocarbazole and isoindolone analogs of (+)K-252a. J Med Chem 50: 433-41 [PMID:17266195]
23. Iida H, Fujikawa R, Kozaki R, Harada R, Hosokawa Y, Ogawara KI and Ohno T. (2020) Pharmacokinetic-Pharmacodynamic-Efficacy Modeling of ONO-7579, a Novel Pan-Tropomyosin Receptor Kinase Inhibitor, in a Murine Xenograft Tumor Model. J Pharmacol Exp Ther 373: 361-369 [PMID:32217770]
24. Ito T, Kinoshita K, Tomizawa M, Shinohara S, Nishii H, Matsushita M, Hattori K, Kohchi Y, Kohchi M and Hayase T et al.. (2022) Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor. J Med Chem 65: 12427-12444 [PMID:36066182]
25. Jones DT, Hutter B, Jäger N, Korshunov A, Kool M, Warnatz HJ, Zichner T, Lambert SR, Ryzhova M and Quang DA et al.. (2013) Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 45: 927-32 [PMID:23817572]
26. Kane JL Jr, Matthews G, Metz M, Kothe M, Liu J and Scholte A. (2015) Tropomyosin-related kinase (Trk) inhibitors Patent number: US9174986B2. Assignee: Genzyme Corp.. Priority date: 10/12/2013. Publication date: 03/11/2015.
27. Katayama R, Gong B, Togashi N, Miyamoto M, Kiga M, Iwasaki S, Kamai Y, Tominaga Y, Takeda Y and Kagoshima Y et al.. (2019) The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nat Commun 10: 3604 [PMID:31399568]
28. Kong NX, Zhou C and Zheng Z. (2021) Heterocyclic compound as trk inhibitor Patent number: US20210147445A1. Assignee: Beijing Innocare Pharma Tech Co Ltd. Priority date: 25/06/2018. Publication date: 20/05/2021.
29. Lee LY, Hernandez D, Rajkhowa T, Smith SC, Raman JR, Nguyen B, Small D and Levis M. (2017) Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood 129: 257-260 [PMID:27908881]
30. Li Y, Xiong Y, Zhang G, Zhang L, Yang W, Yang J, Huang L, Qiao Z, Miao Z and Lin G et al.. (2018) Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model. J Med Chem 61: 11398-11414 [PMID:30480444]
31. Li Z, Hu Y, Wei W, Liguang D, Xiaowei D, Yanqing Y, Yinghui S, Yongxin H, Yong P and Fansheng K. (2018) Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor Patent number: WO2018077246A1. Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Beijing Sailintai Pharmaceutical Technology Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd.. Priority date: 27/10/2017. Publication date: 03/05/2018.
32. Manthey CL, Johnson DL, Illig CR, Tuman RW, Zhou Z, Baker JF, Chaikin MA, Donatelli RR, Franks CF and Zeng L et al.. (2009) JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther 8: 3151-61 [PMID:19887542]
33. Massa SM, Yang T, Xie Y, Shi J, Bilgen M, Joyce JN, Nehama D, Rajadas J and Longo FM. (2010) Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Clin Invest 120: 1774-85 [PMID:20407211]
34. Nanda N, Bilenker JH, Doebele RC, Blake JF, Kolakowski GR, Brandhuber BJ and Andrews SW. (2017) Point mutations in trk inhibitor-resistant cancer and methods relating to the same Patent number: WO2017075107A1. Assignee: Array Biopharma Inc, Loxo Oncology Inc. Priority date: 26/10/2015. Publication date: 04/05/2017.
35. Ohmichi M, Pang L, Ribon V, Gazit A, Levitzki A and Saltiel AR. (1993) The tyrosine kinase inhibitor tyrphostin blocks the cellular actions of nerve growth factor. Biochemistry 32: 4650-8 [PMID:7683492]
36. Pal K, Ciblat S, Albert V, Bruneau-Latour N and Boudreault J. (2021) 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer Patent number: US20210094956A1. Assignee: Pyramid Biosciences Inc. Priority date: 15/12/2017. Publication date: 01/04/2021.
37. Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G and Hatch H et al.. (2010) MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res 70: 1524-33 [PMID:20145145]
38. Patwardhan PP, Ivy KS, Musi E, de Stanchina E and Schwartz GK. (2016) Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. Oncotarget 7: 4093-109 [PMID:26675259]
39. Roa P, Foglizzo V, Harada G, Repetto M, Kulick A, de Stanchina E, de Marchena M, Auwardt S, Sayed Ahmed S and Bremer NV et al.. (2024) Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents. Br J Cancer 131: 601-610 [PMID:38902532]
40. Robertson AG, Banfield MJ, Allen SJ, Dando JA, Mason GG, Tyler SJ, Bennett GS, Brain SD, Clarke AR and Naylor RL et al.. (2001) Identification and structure of the nerve growth factor binding site on TrkA. Biochem Biophys Res Commun 282: 131-41 [PMID:11263982]
41. Sun Y, Xue Y, Liu H, Mu S, Sun P, Sun Y, Wang L, Wang H, Wang J and Wu T et al.. (2023) Discovery of CZS-241: A Potent, Selective, and Orally Available Polo-Like Kinase 4 Inhibitor for the Treatment of Chronic Myeloid Leukemia. J Med Chem 66: 2396-2421 [PMID:36734825]
42. Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL and Shapiro GI et al.. (2015) Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med 373: 428-37 [PMID:26222558]
43. Ultsch MH, Wiesmann C, Simmons LC, Henrich J, Yang M, Reilly D, Bass SH and de Vos AM. (1999) Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and TrkC. J Mol Biol 290: 149-59 [PMID:10388563]
44. Wang T, Ioannidis S, Almeida L, Block MH, Davies AM, Lamb ML, Scott DA, Su M, Zhang HJ and Alimzhanov M et al.. (2011) In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett 21: 2958-61 [PMID:21493067]
45. Wang T, Lamb ML, Block MH, Davies AM, Han Y, Hoffmann E, Ioannidis S, Josey JA, Liu ZY and Lyne PD et al.. (2012) Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett 3: 705-9 [PMID:24900538]
46. Wang Z, Zhang Y, Pinkas DM, Fox AE, Luo J, Huang H, Cui S, Xiang Q, Xu T and Xun Q et al.. (2018) Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2- a]pyrazin-3-ylethynyl)-4-isopropyl- N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2. J Med Chem 61: 7977-7990 [PMID:30075624]
47. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC and Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol 17: 1241-9 [PMID:21095574]
48. Wood ER, Kuyper L, Petrov KG, Hunter RN, Harris PA and Lackey K. (2004) Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg Med Chem Lett 14: 953-7 [PMID:15013000]
49. Wu Y, Zhou W, Gong Y, Yue Y, Deng J and Liu Y. (2019) Tropomyosin receptor kinase inhibitor, preparation method therefor and use thereof Patent number: WO2019233461A1. Assignee: Jiangsu Weikaier Pharmaceutical Technology Co., Ltd.. Priority date: 06/06/2019. Publication date: 12/12/2019.
50. Zhu Y, Ma Y, Zu W, Song J, Wang H, Zhong Y, Li H, Zhang Y, Gao Q and Kong B et al.. (2020) Identification of N-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Derivatives as Novel, Potent, and Selective NF-κB Inducing Kinase (NIK) Inhibitors for the Treatment of Psoriasis. J Med Chem 63: 6748-6773 [PMID:32479083]